$TLRY

Gendel Mitchell purchased $11K of TLRY

Gendel Mitchell (Global General Counsel) purchased 2,500 shares of Tilray Brands, Inc. (TLRY) at $4.43 on 2026-08-06.

Original reporting
SEC EDGAR · Gendel Mitchell
Published Aug 7, 2026, 1:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 2:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TLRY
Neutral
low confidence
Mentioned
$TLRY
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TLRYNeutralLow
01

Why it matters

The disclosed open-market purchase by the company’s Global General Counsel may be interpreted as mild positive sentiment, but it does not provide new company performance, strategy, or regulatory information.

02

Market read

Traders may note the insider buying signal, but the filing lacks fundamental catalysts and is unlikely to drive sustained repricing alone.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide context like prior holdings changes or option exercises.

Relevance 4/10Novelty 5/10Timing: Form 4 filed 2026-08-07, covering purchase dated 2026-08-06.

Background

The article is an SEC Form 4 insider transaction disclosure for Tilray Brands, Inc.

Company-level read

Ticker impact

$TLRYNeutralLow confidence
Context

Tilray insider Gendel Mitchell bought 2,500 shares at $4.43 on 2026-08-06, disclosed via Form 4 filed 2026-08-07.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

The filing is a routine Form 4 transaction with no 10b5-1 plan and no accompanying corporate event, guidance, or operational change.

Market effects

No clear sector read-through from a single legal counsel purchase.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary and may reflect diversification or personal liquidity needs rather than a bullish view on near-term fundamentals.

Key entities

  • Tilray Brands, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Gendel Mitchell

    Global General Counsel who purchased 2,500 shares at $4.43 on 2026-08-06.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.